Red Sox $90M Star’s Future Left in Limbo as Alex Cora Drops Grim Update on Return

4 min read

It is the kind of news no team feels good to deliver—and certainly not this early in the season. The Boston Red Sox, still trying to identify their ground, are now facing uncertainty in a place they were hoping to solidify. All signs highlighted cautious optimism, however, those signs have suddenly dimmed.

Alex Cora did not sugarcoat the situation. When a team is looking for stability and an individual from the list of highest-paid stars is stuck in rehab limbo, the mood transforms. Rob Bradford identified this vibe and said that this transformation just got heavier. He said, “throwing still not going well” and Cora admitted. That is not what you want to hear.

The team knew they would have to be patient coming into this season. Masataka Yoshida, the team’s $90 million star, was not going to hit the mound running after offseason shoulder surgery. Still, thoughts were that he would ramp up by early spring and rejoin the outfield. However, this thought has not become a reality. Instead, Masataka Yoshida’s rehab has stalled. Despite participating in spring training, his throwing enhancement has decreased, forcing the Red Sox to reconsider this star’s timeline. Currently, that timeline could be heading backward.

Alex Cora did not stop when speaking with the media. In a news report relayed by Rob Bradford, he admitted, “Yoshida may head back to Boston this week to get looked at since throwing still not going well”. That is more than just a check-up—it is an emergency brake. The Red Sox assumed to ignore this situation, however, with their star now two years into a five-year deal and unable to manage the defense, frustration is beginning to enhance. The bat could be serviceable; however, if his shoulder is not game-ready, what is next?

Cora said Yoshida (shoulder) may head back to Boston this week to get looked at since throwing still not going well

— Rob Bradford (@bradfo) April 29, 2025

The Red Sox’s hitter went through surgery to repair his torn right labrum over the offseason. The star has not appeared in the majors this season; however, he played in 11 spring training games. At that period, he looked fine and played effectively, with a .286/.286/.400 slash line.

That is the vital question swirling through the team. Masataka Yoshida‘s position as a vital designated hitter can just stretch so far, specifically, in a top-heavy lineup. With the star’s throwing sessions being reconsidered, the Red Sox have been placed in a corner. Does the team continue to wait? Does the team begin to think long-period? Currently, patience is running thin and the Red Sox’s $90 million does not come with a rehab clause.

A ray of hope for the Red Sox

The Red Sox did not just sign Alex Bregman—the team ignited a new period. Currently, it is burning bright enough to cast a long shadow over Masataka Yoshida’s uncertain return. Through 30 games, their new addition is slashing .331/.400/.571 with 40 hits, six homers with a .971 OPS. SI’s J.P. Long reported that Bregman joins Manny Ramirez as the only star to reach more than 40 hits, 5 homers with a .400 OBP in just 30 games. Such a production, specifically, from a late addition, instantly transforms the team’s focus—and Yoshida’s place in it.

While the team initially identified Yoshida as a vital offensive aspect, Bregman’s arrival—and power—has recalibrated thoughts. The third baseman’s three-year, $120 million deal contains opt-outs after each season and it is enhancing the stakes more. Bregman is not just delivering—he is rewriting how the team lines up its long-period aim. In addition, as long as Bregman’s shoulder stalls, the Red Sox’s current $90M conundrum could stay on the shelf.

Yoshida was once the plan—now, he is the variable. With Alex Bregman chasing Manny Ramirez-level eliteness, the Red Sox could already be establishing a future that does not rely on waiting.

The post Red Sox $90M Star’s Future Left in Limbo as Alex Cora Drops Grim Update on Return appeared first on EssentiallySports.